Nimroz Implements Ban on Pakistani Medications Amid National Policy Changes
The health authorities in Nimroz province have announced a ban on the purchase, sale, and distribution of medications manufactured in Pakistan, in line with Kabul’s new policies. This decision aims to gradually phase out these drugs from the market and diversify the country’s sources of pharmaceutical supplies.
New Pharmaceutical Ban in Nimroz and Nationwide Collection Order
The latest announcement from the Nimroz Public Health Directorate signals a new phase in the regulation of the pharmaceutical market in this border province. According to the newly established guidelines, the buying, selling, distributing, and consuming of any Pakistani medications in hospitals, clinics, wholesalers, and pharmacies is strictly prohibited.
Monitoring teams from health authorities have been tasked with collecting and disposing of these items if found, and legal action will be taken against violators.
Implementation of Import Ban Policy and Planning from Kabul
This initiative in Nimroz is part of a broader, incremental program aimed at reducing dependence on the Pakistani pharmaceutical market. Prior decisions have already been made to halt all imports of these medications through all customs points in the country, providing traders with a grace period to finalize their documentation and business transactions.
Simultaneously, specialized committees have been established to manage this transition, develop alternative programs, and diversify sources of pharmaceutical supplies to prevent any shortages or disruptions in the healthcare system.
Expanding Oversight and Challenges in the Drug Market
The process of collecting and banning the supply of Pakistani medications is not limited to Nimroz; in recent months, significant provinces such as Kabul, Herat, and Balkh have also implemented similar plans.
Public health experts believe that the complete success of this initiative requires establishing new import routes, supporting domestic production, and maintaining close oversight of the market to continuously meet the healthcare needs of the population.
